$1.37
11.61% yesterday
Nasdaq, Mar 11, 09:00 pm CET
ISIN
US88875G1013
Symbol
TLSA
Sector
Industry

Tiziana Life Sciences PLC Sponsored ADR Stock price

$1.37
+0.66 93.23% 1M
+0.49 55.68% 6M
+0.67 96.78% YTD
+0.87 174.55% 1Y
+0.33 31.73% 3Y
-0.19 12.12% 5Y
-0.28 16.85% 10Y
Nasdaq, Closing price Tue, Mar 11 2025
-0.18 11.61%
ISIN
US88875G1013
Symbol
TLSA
Sector
Industry

Key metrics

Market capitalization $151.60m
Enterprise Value $133.85m
EV/FCF (TTM) EV/FCF negative
Short interest 1.45%

Is Tiziana Life Sciences PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,814 stocks worldwide.

Tiziana Life Sciences PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Tiziana Life Sciences PLC Sponsored ADR:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Tiziana Life Sciences PLC Sponsored ADR:

Buy
100%

Financial data from Tiziana Life Sciences PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Annually
Dec '22
+/-
%
- -
-
100%
- Direct Costs 0.05 0.05
64% 64%
-
-0.05 -0.05
64% 64%
-
- Selling and Administrative Expenses 4.71 4.71
70% 70%
-
- Research and Development Expense 13 13
2% 2%
-
-18 -18
39% 39%
-
- Depreciation and Amortization 0.05 0.05
64% 64%
-
EBIT (Operating Income) EBIT -18 -18
39% 39%
-
Net Profit -15 -15
34% 34%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tiziana Life Sciences PLC Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tiziana Life Sciences PLC Sponsored ADR Stock News

Positive
Proactive Investors
8 days ago
Tiziana Life Sciences Ltd has filed an investigational new drug application with the Food and Drug Administration for a clinical trial in Amyotrophic Lateral Sclerosis (ALS). Tiziana, which is advancing lead candidate intranasal foralumab, said on Tuesday it planned a phase two trial including 20 patients upon clearance.
Neutral
GlobeNewsWire
8 days ago
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the submission of its Investigational New Drug (IND) application to the U.S. Food an...
Positive
Proactive Investors
13 days ago
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the publication of a groundbreaking study in Nature Neuroscience that demonstrates promising results for its nasal anti-CD3 therapy in treating traumatic brain injury (TBI). TBI is a leading cause of death and disability worldwide, and current treatments fail to address its long-term effects.
More Tiziana Life Sciences PLC Sponsored ADR News

Company Profile

Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Ivor Elrifi
Founded 1998
Website www.tizianalifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today